Head of Pricing & Access Contracting

About the role

The Head of Value & Pricing Spain leads the definition and execution of pricing, value and contracting strategies across the Novartis portfolio in Spain, ensuring an optimal value positioning with payers and authorities and maximising patient access throughout the product lifecycle. The role engages with the Ministry of Health, regional authorities and key stakeholders, turning clinical and economic evidence into sustainable pricing and access decisions.

Key responsibilities

• Define pricing and value strategies for launches and in-market products, lead price negotiations (CIPM) and assess the impact of pricing on access, market share and system sustainability
• Engage with key payers, anticipate regulatory requirements and act as an internal reference on the regulatory environment
• Manage pricing across the product lifecycle, including launches, price revisions, discounts, agreements and loss of exclusivity
• Design payer agreement strategies (risk-sharing, expenditure caps) and lead commercial policy through tenders in hospitals and key accounts, overseeing negotiation, tracking and renewals
• Adapt international pricing guidance to Spain, align with global frameworks and coordinate with international teams on price setting and external reference pricing
• Lead a pricing and/or contracting team and partner with Market Access, HEOR, Commercial, Finance and other functions

Required profile

• 8-10 years' experience in Market Access, Pricing, HEOR or related areas in pharma or strategic consulting
• Proven experience leading and developing teams
• Pricing strategy development, pricing dossier preparation and project management in regulated environments
• Experience with payers, health authorities and international pricing/access teams is a plus
• Degree in health economics, pharmacy, medicine or similar; strong asset: economic modelling / budget impact analysis experience
• Fluent English

Required skills

• Strategic thinking and high-level negotiation in institutional settings
• Integrating clinical, economic and commercial evidence
• Cross-functional leadership without direct authority and executive communication
• Health economics, HTA, market access strategy and go-to-market strategy